TY - JOUR
T1 - Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides
AU - Pavlotsky, Felix
AU - Hodak, Emmilia
AU - Ben Amitay, Dan
AU - Barzilai, Aviv
PY - 2014/9
Y1 - 2014/9
N2 - Background Psoralen plus ultraviolet (UV) A (PUVA) radiation is the preferred treatment for folliculotropic mycosis fungoides (MF) and MF refractory to narrowband (NB) UVB radiation. However, systemic PUVA has many unfavorable side effects and contraindications. Bath PUVA has been found to be a suitable alternative in patients with psoriasis, but data on MF are sparse. Objective The purpose of the study was to evaluate the effectiveness of bath PUVA in the treatment of folliculotropic MF and NB-UVB-refractory early-stage MF. Methods The study group included 26 patients of average age 44 years attending a tertiary medical center in 2004 through 2012, 14 with folliculotropic type and 12 with NB-UVB-refractory early-stage MF who were not amenable for oral PUVA. Treatment consisted of 0.2 mg/L 8-methoxypsoralen bath 3 times weekly followed by UVA irradiation at 0.3 J/cm2 with fixed increments every second session. Results A complete clinical response was achieved in 62% of patients after an average of 33 weeks and a cumulative radiation dose of 158 J/cm 2. Limitations This was a relatively small series. Conclusion Bath PUVA is a good treatment option for superficial folliculotropic MF and NB-UVB-refractory early-stage MF.
AB - Background Psoralen plus ultraviolet (UV) A (PUVA) radiation is the preferred treatment for folliculotropic mycosis fungoides (MF) and MF refractory to narrowband (NB) UVB radiation. However, systemic PUVA has many unfavorable side effects and contraindications. Bath PUVA has been found to be a suitable alternative in patients with psoriasis, but data on MF are sparse. Objective The purpose of the study was to evaluate the effectiveness of bath PUVA in the treatment of folliculotropic MF and NB-UVB-refractory early-stage MF. Methods The study group included 26 patients of average age 44 years attending a tertiary medical center in 2004 through 2012, 14 with folliculotropic type and 12 with NB-UVB-refractory early-stage MF who were not amenable for oral PUVA. Treatment consisted of 0.2 mg/L 8-methoxypsoralen bath 3 times weekly followed by UVA irradiation at 0.3 J/cm2 with fixed increments every second session. Results A complete clinical response was achieved in 62% of patients after an average of 33 weeks and a cumulative radiation dose of 158 J/cm 2. Limitations This was a relatively small series. Conclusion Bath PUVA is a good treatment option for superficial folliculotropic MF and NB-UVB-refractory early-stage MF.
KW - bath psoralen plus ultraviolet A
KW - cutaneous T- cell lymphoma
KW - folliculotropic mycosis fungoides
KW - mycosis fungoides
KW - narrowband ultraviolet B
UR - http://www.scopus.com/inward/record.url?scp=84906316826&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2014.04.011
DO - 10.1016/j.jaad.2014.04.011
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 24836546
AN - SCOPUS:84906316826
SN - 0190-9622
VL - 71
SP - 536
EP - 541
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 3
ER -
